A new German study reports that a combination of the AstraZeneca and BioNTech vaccines triggers a remarkably stronger immune response than sticking with one kind of shot.
Follow RT on A Spanish study has suggested that administering a second dose of Pfizer to those who received AstraZeneca as their first dose is safe. It saw antibodies increase seven-fold compared to those who were given no second jab at all.
The CombivacS study, which enrolled 676 participants who had already received a first dose of AstraZeneca and gave them a second dose of Pfizer, has produced positive preliminary results. Of the total cohort, 450 people were given Pfizer as their second dose, and the remaining 226 have not received any second dose and are being observed as the control group.
Published on Tuesday, the study, launched by the Carlos III Health Institute, reported that the combination was both safe and effective. Jesus Antonio Frias, coordinator of the ISCIII Clinical Research Network, said,
Mix-and-Match COVID Vaccines Trigger Potent Immune Response
Preliminary results from a trial of more than 600 people are the first to show the benefits of combining different vaccines
Print
Countries with fluctuating supplies of COVID-19 vaccines could benefit from using different vaccines for the first and second dose. Credit: Christof Stache
Advertisement
Vaccinating people with both the Oxford–AstraZeneca and Pfizer–BioNTech COVID-19 vaccines produces a potent immune response against the virus SARS-CoV-2, researchers conducting a study in Spain have found.
Preliminary results from the trial of more than 600 people announced in an online presentation on May 18 are the first to show the benefits of combining different coronavirus vaccines. A UK trial of a similar strategy reported safety data last week, and is expected to deliver further findings on immune responses soon.
Share:
Masimo (NASDAQ:MASI) announced today the findings of a study published in the
Journal of Applied Physiology in which Dr. Marina García-de-Acilu and colleagues at the Vall d Hebron University Hospital in Barcelona evaluated the utility of Masimo PVi
® as a noninvasive method of predicting preload responsiveness in patients treated with nasal high-flow (NHF) therapy. They found that PVi may identify preload responders and noted that PVi may therefore be used in the day-to-day clinical decision-making process in critically ill patients treated with NHF, helping to provide adequate resuscitation volume.
1 More than 100 independent studies have demonstrated the utility of PVi as an indicator of fluid responsiveness.